Clinical trials: Androgens
Circulating Tumor Cell, Metastatic Prostate Cancer
Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)
After failure on docetaxel, which has been the standard first line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), several treatment options are currently available.
- Trial name
- CABA-V7 (NCT03050866)
- Testing
- Cabazitaxel, Antihistamine, Corticosteroid
- Where
- 9 sites in Netherlands
- Volunteers
- 140 people
- Sponsor
- Erasmus Medical Center
Prostate Cancer
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
The purpose of this study is to determine the safety and efficacy of enzalutamide vs bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have disease progression despite primary androgen…
- Trial name
- STRIVE (NCT01664923)
- Testing
- Enzalutamide, Bicalutamide
- Where
- 109 sites in United States
- Volunteers
- 396 people
- Sponsor
- Pfizer
Infertility, Female, Ovarian Reserve
hCG Priming in Women With Low Ovarian Reserve
The aim of this trial is to examine the possible effects of hCG administration for eight weeks prior to IVF/ICSI in women with low ovarian reserve.
- Conditions
- Infertility, Female, Ovarian Reserve, In Vitro Fertilization
- Trial name
- NCT04643925
- Testing
- Ovitrelle
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Evaluations, Diagnostic Self, Treatment Adherence
Impact of Vitamin D Supplementation on Cardiometabolic Status and Androgen Profile in Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is a heterogeneous disorder of reproductive, endocrine and metabolic functions. Vitamin D has an influence on metabolic and reproductive functions.
- Trial name
- NCT04117750
- Testing
- cholecalciferol (vit D3)
- Where
- Egypt
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Disorders of Sexual Development
Disorders of Sexual Development and Gonadal Tumor Risk
Disorders of Sexual Development are rare and represent a spectrum of heterogeneous pathologies. The risk of developing a malignant gonadal germ cell tumor (MGCT) exists and varies according to the etiology.
- Trial name
- DEV-GEN-RiTuGo (NCT06682078)
- Testing
- Not applicable . Non-interventional retrospective study, only on datas.
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Hospices Civils de Lyon
Dihydrotestosterone, Testosterone
Influence of Creatine Monohydrate Supplementation on Androgens and Global Hair Assessments
This study is a randomized, double-blind, placebo-controlled trial examining the effects of creatine monohydrate supplementation on androgens and hair loss in free-living adult males.
- Conditions
- Dihydrotestosterone, Testosterone, Hair Loss
- Trial name
- NCT04298840
- Testing
- Creatine Monohydrate Supplementation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Texas Tech University
Prostate Cancer
Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases
The aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific survival, time to castration-resistance, time to progression and quality of life in patients with a…
- Trial name
- g-RAMPP (NCT02454543)
- Testing
- Radical prostatectomy, Best systemic therapy
- Where
- Germany
- Volunteers
- 452 people
- Sponsor
- Martini-Klinik am UKE GmbH
Prostate Cancer
Training for Men Undergoing Androgen Deprivation Therapy.
The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).
- Trial name
- ADT-train (NCT06449664)
- Testing
- ADT-train
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- The Swedish School of Sport and Health Sciences
Metastatic Castration-resistant Prostate Cancer
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors.
- Trial name
- NCT02047253
- Testing
- Carfilzomib, Dexamethasone, Acyclovir
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Prostate Cancer
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
This is an open label study designed to examine the effects on concurrent administration of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone in subjects with symptomatic castrate resistant prostate cancer and with…
- Trial name
- eRADicAte (NCT02097303)
- Testing
- Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Carolina Research Professionals, LLC
Prostate Cancer, Metastases
A Research Study for Patients With Prostate Cancer
The purpose of this study is to evaluate the activity of romidepsin (depsipeptide,FK228) in patients with metastatic prostate cancer who have developed a rising prostate specific antigen (PSA) while undergoing hormonal therapy.
- Trial name
- NCT00106418
- Testing
- Romidepsin
- Volunteers
- 35 people
- Sponsor
- Celgene
Metastatic Hormone Sensitive Prostate Cancer
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
The purpose of this study was to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review.
- Trial name
- ARCHES (NCT02677896)
- Testing
- Enzalutamide
- Where
- 203 sites in United States, Argentina and 22 more
- Volunteers
- 1,150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide.
- Conditions
- Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT03016741
- Testing
- GnRH agonist/antagonist, Prednisone, Abiraterone Acetate
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University
Prostate Cancer
Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database
In prostate cancer, whether advanced or localized, hormone therapy is a key treatment. These therapies work by lowering male hormone levels to slow the growth of cancer.
- Trial name
- NCT06902441
- Where
- France
- Volunteers
- 52,000 people
- Sponsor
- University Hospital, Caen
Prostate Cancer
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen…
- Trial name
- PREVAIL (NCT01212991)
- Testing
- Enzalutamide
- Where
- 269 sites in United States, Australia and 20 more
- Volunteers
- 1,717 people
- Sponsor
- Pfizer
Erectile Dysfunction Due to Arterial Disease, Atheroscleroses
TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men
Aim. To study the effect of different intensities of statin therapy on androgen status and erectile function in men aged 40-65 years with high and very high cardiovascular risk.
- Conditions
- Erectile Dysfunction Due to Arterial Disease, Atheroscleroses, Erectile Disfunction, Endothelial Dysfunction
- Trial name
- NCT07460960
- Testing
- Pitavastatin 1-4 mg daily, Rosuvastatin 20-40 mg daily
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Lomonosov Moscow State University Medical Research and Educational Center
Triple Negative Breast Neoplasms
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.
- Trial name
- ABBICAR (NCT06365788)
- Testing
- Abemaciclib, Bicalutamide
- Where
- 6 sites in Belgium
- Volunteers
- 53 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
Background: Enzalutamide is a hormone therapy that is used to treat advanced prostate cancer. It is given after chemotherapy and surgery to help the body destroy the cancer cells.
- Trial name
- NCT01867333
- Testing
- PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM, PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM, Enzalutamide
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Neoadjuvant Therapy
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH) agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer in patients treated by radical prostatectomy…
- Conditions
- Prostate Cancer, Neoadjuvant Therapy, Androgen Antagonists, Prostatectomy
- Trial name
- ARNEO (NCT03080116)
- Testing
- ARN-509, Degarelix
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer, Stereotactic Body Radiation Therapy
START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor…
- Trial name
- START-MET (NCT05209243)
- Testing
- SBRT, STANDARD OF CARE
- Where
- 2 sites in Spain
- Volunteers
- 266 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.